Bone – Osteosarcoma showing a moderate to strong SATB2 positivity of tumor cells.
Bone - Osteosarcoma showing a moderate to strong SATB2 positivity of tumor cells. Bone – Osteosarcoma with strong SATB2 immunostaining of all tumor cells.
Bone - Osteosarcoma with strong SATB2 immunostaining of all tumor cells. Breast – SATB2 negative invasive breast cancer of no special type (NST).
Breast - SATB2 negative invasive breast cancer of no special type (NST). Breast – SATB2 negative invasive lobular breast cancer.
Breast - SATB2 negative invasive lobular breast cancer. Colon – Colorectal adenocarcinoma exhibiting only a weak SATB2 immunostaining of tumor cells.
Colon - Colorectal adenocarcinoma exhibiting only a weak SATB2 immunostaining of tumor cells. Colon – Colorectal adenocarcinoma showing strong SATB2 immunostaining of all tumor cells.
Colon - Colorectal adenocarcinoma showing strong SATB2 immunostaining of all tumor cells. Colon – Colorectal adenocarcinoma with strong SATB2 positivity of tumor cells.
Colon - Colorectal adenocarcinoma with strong SATB2 positivity of tumor cells. Colon – Colorectal adenoma with intense SATB2 immunostaining of tumor cells.
Colon - Colorectal adenoma with intense SATB2 immunostaining of tumor cells. Colon – Neuroendocrine tumor showing strong SATB2 positivity of tumor cells.
Colon - Neuroendocrine tumor showing strong SATB2 positivity of tumor cells. Esophagus – Adenocarcinoma showing a moderate to strong SATB2 staining of tumor cells.
Esophagus - Adenocarcinoma showing a moderate to strong SATB2 staining of tumor cells. Esophagus – Adenocarcinoma with a weak to moderate SATB2 positivity of tumor cells.
Esophagus - Adenocarcinoma with a weak to moderate SATB2 positivity of tumor cells. Esophagus – Squamous cell carcinoma depicting a strong SATB2 positivity of the majority of tumor cells.
Esophagus - Squamous cell carcinoma depicting a strong SATB2 positivity of the majority of tumor cells. Kidney – Oncocytoma exhibiting a moderate SATB2 immunostaining of a fraction of tumor cells.
Kidney - Oncocytoma exhibiting a moderate SATB2 immunostaining of a fraction of tumor cells. Kidney – Papillary renal cell carcinoma showing moderate SATB2 immunostaining of tumor cells.
Kidney - Papillary renal cell carcinoma showing moderate SATB2 immunostaining of tumor cells. Kidney – Papillary renal cell carcinoma showing weak SATB2 immunostaining of tumor cells.
Kidney - Papillary renal cell carcinoma showing weak SATB2 immunostaining of tumor cells. Kidney – SATB2 negative clear cell renal cell carcinoma.
Kidney - SATB2 negative clear cell renal cell carcinoma. Kidney – SATB2 negative papillary renal cell carcinoma.
Kidney - SATB2 negative papillary renal cell carcinoma. Liver – SATB2 negative cholangiocellular carcinoma.
Liver - SATB2 negative cholangiocellular carcinoma. Lung – SATB2 negative adenocarcinoma.
Lung - SATB2 negative adenocarcinoma. Lymph node – SATB2 negative diffuse large B-cell lymphoma.
Lymph node - SATB2 negative diffuse large B-cell lymphoma. Ovary – SATB2 negative clear cell carcinoma.
Ovary - SATB2 negative clear cell carcinoma. Ovary – SATB2 negative serous high-grade carcinoma.
Ovary - SATB2 negative serous high-grade carcinoma. Pancreas – Neuroendocrine tumor showing a faint SATB2 immunostaining of tumor cells.
Pancreas - Neuroendocrine tumor showing a faint SATB2 immunostaining of tumor cells. Pancreas – SATB2 negative ductal adenocarcinoma.
Pancreas - SATB2 negative ductal adenocarcinoma. Prostate – SATB2 negative adenocarcinoma (Gleason 3+3=6).
Prostate - SATB2 negative adenocarcinoma (Gleason 3+3=6). Salivary gland – SATB2 negative pleomorphic adenoma.
Salivary gland - SATB2 negative pleomorphic adenoma. Skin – Merkel cell carcinoma showing a moderate to strong SATB2 immunostaining of all tumor cells.
Skin - Merkel cell carcinoma showing a moderate to strong SATB2 immunostaining of all tumor cells. Soft tissue – Leiomyosarcoma showing a faint SATB2 immunostaining of most tumor cells.
Soft tissue - Leiomyosarcoma showing a faint SATB2 immunostaining of most tumor cells. Stomach – Gastric adenocarcinoma (diffuse type) showing a weak to moderate SATB2 immunostaining of tumor cells.
Stomach - Gastric adenocarcinoma (diffuse type) showing a weak to moderate SATB2 immunostaining of tumor cells. Stomach – Gastric adenocarcinoma exhibiting a weak to moderate SATB2 positivity of tumor cells.
Stomach - Gastric adenocarcinoma exhibiting a weak to moderate SATB2 positivity of tumor cells. Stomach – SATB2 negative gastrointestinal stromal tumor (GIST).
Stomach - SATB2 negative gastrointestinal stromal tumor (GIST). Testis – SATB2 negative seminoma.
Testis - SATB2 negative seminoma. Thyroid – SATB2 negative medullary cancer.
Thyroid - SATB2 negative medullary cancer. Urinary bladder – Muscle-invasive urothelial carcinoma exhibiting a moderate SATB2 immunostaining of a fraction of tumor cells.
Urinary bladder - Muscle-invasive urothelial carcinoma exhibiting a moderate SATB2 immunostaining of a fraction of tumor cells. Urinary bladder – Small cell carcinoma with a moderate intensity SATB2 immunostaining of the majority of tumor cells.
Urinary bladder - Small cell carcinoma with a moderate intensity SATB2 immunostaining of the majority of tumor cells. Urinary bladder – SATB2 negative muscle-invasive urothelial carcinoma.
Urinary bladder - SATB2 negative muscle-invasive urothelial carcinoma. Uterus – Endometroid endometrium carcinoma with weak to moderate SATB2 immunostaining of the majority of tumor cells.
Uterus - Endometroid endometrium carcinoma with weak to moderate SATB2 immunostaining of the majority of tumor cells. Uterus, cervix – SATB2 negative squamous cell carcinoma.
Uterus, cervix - SATB2 negative squamous cell carcinoma.